Ribociclib Succinate and Letrozole
Ribociclib Succinate and Letrozole · Cyclin-Dependent Kinase 4/6 (CDK4/6) Inhibitor
Indications & Uses
HR-positive, HER2-negative advanced, metastatic, or high-risk early Breast Cancer.
Contraindications
Hypersensitivity to active ingredient or any formulation excipients.
Side Effects & Warnings
Neutropenia, leukopenia, diarrhea (prominent with abemaciclib), fatigue, infections, interstitial lung disease.
Drug & Dietary Interactions
Strong CYP3A inhibitors increase exposure; monitor complete blood counts.
For educational and informational purposes only. Do not alter medication doses or regimens without consulting your licensed oncology physician or care team.
Patient & Caregiver Support
Ask About This Medication
Connect with an ONC-ORG counselor regarding drug access, copay relief, patient assistance programs, or related clinical trials.